1. C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay
- Author
-
Graciela Russomando, Diana Sanabria, Chyntia Carolina Díaz Acosta, Leticia Rojas, Laura Franco, Rossana Arenas, Giovanni Delogu, Mame Diarra Bousso Ndiaye, Rim Bayaa, Niaina Rakotosamimanana, Delia Goletti, and Jonathan Hoffmann
- Subjects
pulmonary tuberculosis ,host biomarkers ,treatment immunomonitoring ,plasma protein signature ,immunodiagnostic ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionNew diagnostic tools are needed to rapidly assess the efficacy of pulmonary tuberculosis (PTB) treatment. The aim of this study was to evaluate several immune biomarkers in an observational and cross-sectional cohort study conducted in Paraguay.MethodsThirty-two patients with clinically and microbiologically confirmed PTB were evaluated before starting treatment (T0), after 2 months of treatment (T1) and at the end of treatment (T2). At each timepoint plasma levels of IFN-y, 17 pro- and anti-inflammatory cytokines/chemokines and complement factors C1q, C3 and C4 were assessed in unstimulated and Mtb-specific stimulated whole blood samples using QuantiFERON-TB gold plus and recombinant Mycobacterium smegmatis heparin binding hemagglutinin (rmsHBHA) as stimulation antigen. Complete blood counts and liver enzyme assays were also evaluated and correlated with biomarker levels in plasma.ResultsIn unstimulated plasma, C1q (P
- Published
- 2024
- Full Text
- View/download PDF